{"relation": [["", "Main: Linagliptin 5mg QD", "Main: Metformin 500mg BID", "Main: Metformin 1000mg BID", "Main: Linagliptin 2.5mg / Metformin 500mg BID", "Main: Linagliptin 2.5mg / Metformin 1000mg BID", "APG: Linagliptin 5mg QD", "APG: Linagliptin 2.5mg / Metformin 1000mg BID", "Total"], ["Description", "Main Group: Patients received linagliptin 5mg QD, administered oral as tablet.", "Main Group: Patients received metformin 500mg BID, administered oral as tablet.", "Main Group: Patients received metformin 1000mg BID, administered oral as tablet.", "Main Group: Patients received linagliptin 2.5mg and metformin 500mg BID, administered oral as fixed dose combination (FDC) tablet.", "Main Group: Patients received linagliptin 2.5mg and metformin 1000mg BID, administered oral as fixed dose combination (FDC) tablet.", "Additional parallel group (APG): Patients received linagliptin 5mg QD, administered oral as tablet. (Data up to week 12)", "Additional parallel group (APG): Patients received linagliptin 2.5mg and metformin 1000mg BID, administered oral as fixed dose combination (FDC) tablet. (Data up to week 12)", "Total of all reporting groups"]], "pageTitle": "Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug na\u00efve Type 2 Patients - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT01708902?show_locs=Y", "hasHeader": true, "headerPosition": "MIXED", "tableType": "RELATION", "tableNum": 6, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988650.6/warc/CC-MAIN-20150728002308-00017-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 865446151, "recordOffset": 865428750, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Reporting Groups After 2-weeks placebo run-in in the main group, 730 of 733 randomised patients were treated in a double-blind fashion for 24 weeks. In the additional parallel group (APG), all of 143 randomised patients with HbA1c >=11% were treated for 24 weeks (the first 12 weeks were double-blind). There was a 1-week follow-up period after treatment. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: linagliptin2.5mg/metformin1000mg Drug: linagliptin 5mg Drug: Metformin 500mg Drug: linagliptin2.5mg/metformin500mg Drug: Metformin 1000mg Interventions: Diabetes Mellitus, Type 2", "textAfterTable": "\u00a0 \u00a0 Main: Linagliptin 5mg QD \u00a0 \u00a0 Main: Metformin 500mg BID \u00a0 \u00a0 Main: Metformin 1000mg BID \u00a0 \u00a0 Main: Linagliptin 2.5mg / Metformin 500mg BID \u00a0 \u00a0 Main: Linagliptin 2.5mg / Metformin 1000mg BID \u00a0 \u00a0 APG: Linagliptin 5mg QD \u00a0 \u00a0 APG: Linagliptin 2.5mg / Metformin 1000mg BID \u00a0 STARTED \u00a0 \u00a0 147 \u00a0 \u00a0 145 \u00a0 \u00a0 144 \u00a0 \u00a0 147 \u00a0 \u00a0 147 \u00a0 \u00a0 71 \u00a0 \u00a0 72 \u00a0 COMPLETED \u00a0 \u00a0 130 \u00a0 \u00a0 137 \u00a0 \u00a0 127 \u00a0 \u00a0 137 \u00a0 \u00a0 131 \u00a0 \u00a0 64 \u00a0 \u00a0 65 \u00a0", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}